SCHEMBL20508030

SCHEMBL20508030

Cc1cc(-c2ncc(CNC(=O)c3ncc(-c4ccccn4)s3)cc2C)ccn1

nearest known ligand 0.56

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ WNT3A P56704 10/20 0.56
▸ PORCN Q9H237 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20508144 0.92 WNT3A (0.52) WNT3APORCN
SCHEMBL20508084 0.90 WNT3A (0.48) WNT3APORCN
SCHEMBL20508199 0.90 WNT3A (0.47) WNT3A
SCHEMBL20508058 0.89 WNT3A (0.59) WNT3APORCN
SCHEMBL20508147 0.88 WNT3A (0.49) WNT3APORCN
SCHEMBL20507968 0.87 WNT3A (0.54) WNT3APORCN
SCHEMBL20508100 0.87 WNT3A (0.47) WNT3APORCN
SCHEMBL20507923 0.86 WNT3A (0.45) WNT3A
SCHEMBL20508074 0.86 WNT3A (0.47) WNT3APORCN
SCHEMBL20508018 0.85 HDAC1 (0.49) WNT3APORCN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3388428-B1 FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR SUZHOU SINOVENT PHARMACEUTICALS COMPANY (CN) 2021-08-04 — — EP claimed
US-10821104-B2 Five-membered heterocyclic amides WNT pathway inhibitor Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) 2020-11-03 — — US claimed
EP-3388428-A1 FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR Suzhou Sinovent Pharmaceuticals Company (CN) 2018-10-17 — — EP claimed
US-20180271846-A1 FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) 2018-09-27 — — US claimed
EP-3388428-B1 FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR SUZHOU SINOVENT PHARMACEUTICALS COMPANY (CN) 2021-08-04 — — EP disclosed
US-10821104-B2 Five-membered heterocyclic amides WNT pathway inhibitor Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) 2020-11-03 — — US disclosed
US-10821104-B2 Five-membered heterocyclic amides WNT pathway inhibitor Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) 2020-11-03 — — US disclosed
EP-3388428-A1 FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR Suzhou Sinovent Pharmaceuticals Company (CN) 2018-10-17 — — EP disclosed
US-20180271846-A1 FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) 2018-09-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180271846-A1 FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR WNT1, WNT3, WNT3A WNT3A 3/4885PORCN 736/4885
US-10821104-B2 Five-membered heterocyclic amides WNT pathway inhibitor WNT1, WNT3, WNT3A WNT3A 3/4885PORCN 516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback